Michael Killpack
Internal Medicine · Sandy, UTNPI 1588714091
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 100.0% of the total across 109 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 28 manufacturers, the largest accounting for just 15.7% — the pattern of someone who eats at a lot of different presentations. Reporting peaked in 2019 at $873 and has fallen 98.4% since, to $14 in 2022.
Across 109 payments — averaging $15.30 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$261
- Astellas Pharma US Inc$167
- Amgen$158
- Amarin Pharma, Inc.$131
- AstraZeneca$118
- Sanofi-aventis U.S. LLC$118
- plus $713 from 22 others
Across 412 payments — averaging $4871.63 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Genentech, Inc.$495K
- Eisai Inc.$320K
- Sebela Pharmaceuticals Inc.$248K
- Mitsubishi Tanabe Pharma Development America, Inc.$231K
- Biohaven Pharmaceuticals, Inc.$221K
- AstraZeneca$111K
- plus $382K from 10 others
What the payments were for
- Food & beverage$1,667100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie(2 entities) | 18 | $261 |
| Astellas Pharma US Inc | 11 | $167 |
| Amgen | 9 | $158 |
| Amarin Pharma, Inc. | 7 | $131 |
| AstraZeneca | 8 | $118 |
| Sanofi-aventis U.S. LLC | 8 | $118 |
| Merck | 8 | $104 |
| Alkermes, Inc. | 5 | $87 |
| Pfizer | 5 | $79 |
| Novo Nordisk | 6 | $78 |
| GSK | 3 | $40 |
| Gilead | 2 | $32 |
| Johnson & Johnson | 2 | $32 |
| Sanofi Pasteur Inc. | 2 | $31 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 2 | $25 |
| Boston Scientific | 1 | $22 |
| Boehringer Ingelheim | 1 | $21 |
| Otsuka America Pharmaceutical, Inc. | 1 | $20 |
| Acadia Pharmaceuticals Inc | 1 | $17 |
| Seqirus USA Inc | 1 | $17 |
| Novartis | 1 | $17 |
| Insmed, Inc. | 1 | $16 |
| Mannkind Corporation | 1 | $15 |
| Medtronic | 1 | $13 |
| Eisai Inc. | 1 | $13 |
| Teva Pharmaceuticals USA, Inc. | 1 | $12 |
| Kowa Pharmaceuticals America, Inc. | 1 | $11 |
| Lilly USA, LLC | 1 | $11 |
How this compares
$1,667 in reported general payments places this provider in the 80th percentile of 496 internal medicine providers in Utah.
Other internal medicine in Sandy
- Barbara RizzardiSandy$30K
- James StewartSandy$5K
- Willard DereSalt Lake City$4.7M
- Kenneth SchaecherWest Valley City$333K
- Steven CallSpringville$178K
- James ChamberlainSalt Lake City$106K
- Alexander PastuszakSalt Lake City$87K
- Zameer AbedinSalt Lake City$83K
- Kashif MemonVernal$73K
- Gerald GleichSalt Lake City$22K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.